deaths (OS)

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus Standard of Care (SoC)
durvalumab alone vs. Standard of Care (SoC) 1 certainty unassessable-34%